Emergent BioSolutions Inc.
Robbins LLP served as lead counsel in shareholder derivative litigation involving alleged breaches of fiduciary duty arising from the defendants' failure to address the company's regulatory non-compliance, which led to the termination of Emergent's contracts to manufacture COVID-19 vaccine bulk drug substance as part of the U.S. government's "Operation Warp Speed" pandemic response and left the Company on the brink of insolvency. Robbins LLP led a coordinated multi-jurisdictional litigation effort that culminated in a $15 million payment to Emergent and significant governance reforms tailored to address the oversight lapses and internal controls deficiencies Plaintiffs contend left the Company unable to demonstrate compliance with U.S. Food and Drug Administration drug manufacturing standards.
In re Emergent BioSolutions Inc., Stockholder Derivative Litigation, Case No. 8:21-cv-01595-DLB (D. Md. Aug. 6, 2025).
Protect your